ea0073oc11.2 | Oral Communications 11: Adrenal and Cardiovascular Endocrinoloyg | ECE2021
Bothou Christina
, Sharma Ashish
, Shapiro Igor
, Adrian Oo
, Kim Baek
, Beuschlein Felix
, Perge Pal
, Igaz Peter
, Ronchi Cristina L.
, Hantel Constanze
Current systemic treatment options for patients with ACCs are far from being satisfactory. DNA damage/repair mechanisms, which involve e.g. ATM/ATR-signalling or RRM1/RRM2 encoded ribonucleotide reductase (RNR) activation commonly contribute to drug resistance. Moreover, also the regulation of RRM2b, the p53-induced alternative to RRM2, is of unclear importance for ACC. Upon extensive drug screening, including a large panel of classical chemotherapies (doxorubicin, etoposide, ...